期刊
MOLECULAR AND CELLULAR ENDOCRINOLOGY
卷 276, 期 1-2, 页码 1-9出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2007.06.001
关键词
phosphorylated prolactin; S179D prolactin; cell proliferation; cell differentiation; apoptosis; anti-angiogenesis; anti-inflammatory; selective prolactin receptor modulator; prolactin-receptor interactions; prolactin signaling; prolactin antagonists
资金
- Intramural NIH HHS [Z01 DK061005] Funding Source: Medline
- NIDDK NIH HHS [R01 DK061005-04, DK 61005, R01 DK061005] Funding Source: Medline
The aims of this review are three-fold: first, to collate what is known about the production and activities of phosphorylated prolactin (PRL), the latter largely, but not exclusively, as illustrated through the use of the molecular mimic, S 179D PRL; second, to apply this and related knowledge to produce an updated model of prolactin-receptor interactions that may apply to other members of this cytokine super-family; and third, to promote a shift in the current paradigm for the development of clinically important growth antagonists. This third aim explains the title since, based on results with S 179D PRL, it is proposed that agents which signal to antagonistic ends may be better therapeutics than pure antagonists-hence antagonistic agony. Since S 179D PRL is not a pure antagonist, we have proposed the term selective prolactin receptor modulator (SPeRM) for this and like molecules. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据